Autologous Epstein Barr virus-specific adoptive T cell therapy continues to show promise as a novel treatment for patients with progressive MS. In a phase 1 clinical trial in Queensland, EBV-specific T cells were successfully generated from peripheral blood mononuclear cells in 11 of 13 patients with either primary or secondary progressive disease. The two MS ...
Already a member?
Enter your email to keep reading.